Diffuse gliomas with FGFR3::TACC3 fusion are not recognized as a distinct tumor type in the 2021 WHO classification of CNS tumors, which is in keeping with their clinical and epigenetic heterogeneity. This evidence concerns the gene TACC3 and central nervous system neoplasm.